Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

FDA Accepts For Review Spectrum's Response On ZEVALIN As A Class 1 Submission, And Establishes September 7, 2009 As Decision Date
Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial stage biotechnology company with a focus on oncology, announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the resubmission to the Company"s supplement to the biologics license application for ZEVALIN (ibritumomab tiuxetan) in the first line consolidation setting on July 8, 2009. The FDA considers the review as a Class 1 submission to their complete response letter of July 2, 2009. Therefore, the user fee goal date is September 7, 2009.

Details Remain Unclear On Medicare Drug Deal
The White House formally announced the drug manufacturers" plan to lower Medicare drug prices Monday. While details still remain unclear, it appears drug companies may benefit from the deal.
News of the day
New Service Will Relieve Pressure On GPs And NHS, UK
A new self-care service which will give people with pandemic swine flu symptoms fast access to antivirals was launched today by Health Secretary Andy Burnham.
Medical Devices

MiR-196a Promotes The Metastases Of Tumors

MicroRNAs are small RNA molecules of 20-25 nucleotides length, regulating gene expression by inhibition of transcription or translation of proteins. High levels of miR-196a, a microRNA suppressing the expression of specific homebox genes that are of high relevance for the development of the human embryo, activated oncogenic pathways inside human tumor cells and induced tumor cell dissemination. miR-196a increased the chemosensitivity towards platin derivatives such as cisplatin and oxaliplatin and might be a useful biomarker. Analysing the microRNA expression pattern in pancreatic cancer by microRNA chip analyses, Carlo Croce found that 75% of tumours expressed miR-196a at a high level, predicting poor patient survival. Yekta and colleagues first described a miR-196a-directed cleavage of specific homebox genes (HoxB8, HoxC8, HoxD8 and HoxA7) in mouse embryos and mammalian cells. As a tumour-suppressive effect of HoxC8 has been previously discussed in humans, it has been hypothesized that miR-196a might promote tumour progression. A research article published on May 7, 2009 in the World Journal of Gastroenterology addresses this question. In fact, Carl Schimanski and colleagues report that miR-196a supports tumour cell detachment and tumour cell dissemination in vitro via activation of the AKT pathway. In order to confirm these experiments, they performed animal studies with immune suppressed mice which received a tail vein injection of human tumour cells. Pretreatment of tumour cells with miR-196a lead to significantly more lung metastases in these animals. Therefore, the authors conclude that miR-196a does support the development of metastases by exerting a pro-oncogenic function. Noteworthy, several other microRNA have been described that exert pro-oncogenic funtions, such as miR-17-92 which is significantly increased in small-cell lung cancer and decreases survival by inhibition of tumour-suppressor genes PTEN and RB2. The exact mode of function of miR-196a still needs to be analysed. Reference: Schimanski CC, Frerichs K, Rahman F, Berger M, Lang H, Galle PR, Moehler M, Gockel I. High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol 2009; 15(17): 2089-2096 http://www.wjgnet.com/1007-9327/15/2089.asp Correspondence to: Carl Christoph Schimanski, First Department of Internal Medicine, Johannes Gutenberg University of Mainz, Langenbeckstrasse 1, 55131 Mainz, Germany. Lin Tian World Journal of Gastroenterology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009